Repros Therapeutics Inc. today announced that it has entered into a definitive agreement under which Allergan plc will acquire Repros for a cash payment of $0.67 per share.
Repros Therapeutics Inc. today announced that it has entered into a definitive agreement under which Allergan plc will acquire Repros for a cash payment of $0.67 per share.